Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) shares rose 7.4% on Wednesday . The company traded as high as $6.44 and last traded at $6.44. 1,000 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 6,218 shares. The stock had previously closed at $5.9966.
Wall Street Analyst Weigh In
Separately, Zacks Research raised shares of Oxford BioMedica to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Oxford BioMedica presently has an average rating of “Hold”.
Get Our Latest Analysis on Oxford BioMedica
Oxford BioMedica Trading Down 2.9%
About Oxford BioMedica
Oxford BioMedica plc is a United Kingdom-based contract development and manufacturing organization (CDMO) focused on cell and gene therapies. The company helps biotechnology and pharmaceutical customers develop, test, and manufacture advanced therapies, with expertise in viral-vector technologies used to deliver genetic material into cells.
Its services include process and analytical development, clinical and commercial manufacturing, quality testing, regulatory support, and related research services.
See Also
- Five stocks we like better than Oxford BioMedica
- Full Throttle: Kratos and GE Fire Up a Next-Gen Defense Engine
- Sandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?
- These 4 Companies Are Monetizing AI Today
- Quantum and Rare Earths? Implications of the Pasqal/USAR Partnership
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
